All Oncology News

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Evan S. Wu, MD, PhD, delves into the one of the most pivotal aspects of designing a successful bridging study: the selection of clinical end points.

Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.

Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.

Sarah Sammons, MD, discusses data with T-DXd in frontline HER2-positive breast cancer and other ADCs in the breast cancer space.

The FDA approved tafasitamab-cxix plus lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma.

Venetoclax plus rituximab displayed OS and PFS benefits vs BR after long-term follow-up in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

Bexobrutideg was safe and displayed an ORR of 84.2% in relapsed/refractory Waldenström macroglobulinemia.

Electric field device placed on the scalp, along with immunotherapy and chemotherapy may help patients with glioblastoma live longer, particularly those with large, inoperable tumors.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

Health Canada has approved a quizartinib-based regimen for the treatment of patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

Venetoclax plus azacitidine did not yield an OS benefit vs placebo plus azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes.

Jonathan Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET–overexpressing, nonsquamous, EGFR wild-type advanced NSCLC.

Treatment with ibrutinib plus venetoclax and a CD20 monoclonal antibody induced high MRD negativity rates vs ibrutinib/anti-CD20 in untreated MCL.

Cathy Eng, MD, FACP, FASCO, highlights the significance of the FDA approval of retifanlimab for managing locally recurrent or metastatic SCAC.

PROs were improved with pirtobrutinib among evaluable patient with CLL/SLL treated during the BRUIN CLL-321 trial.

Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.

A matching-adjusted indirect comparison of zanubrutinib and acalabrutinib/venetoclax showed favorability towards zanubrutinib in patients with CLL.

Isa-KRd significantly improved the 1-year MRD negativity rate compared with KRd alone in newly diagnosed patients with multiple myeloma.

Results from dose level G of MagnetisMM-6 found high response rates with an elranatamab triplet in patients with newly diagnosed multiple myeloma.

The FDA has granted orphan drug designation to CID-078 for the treatment of patients with small cell lung cancer.

Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.